Vitamins and Aging: Pathways to NAD+ Synthesis  by Denu, John M.
Leading Edge
PreviewsVitamins and Aging:  
Pathways to NAD+ Synthesis
John M. Denu1,*
1Department of Biomolecular Chemistry, School of Medicine and Public Health, University of Wisconsin, 1300 University 
 Avenue, Madison, WI 53706, USA
*Correspondence: jmdenu@wisc.edu
DOI 10.1016/j.cell.2007.04.023
Recent genetic evidence reveals additional salvage pathways for NAD+ synthesis. In this 
issue, Belenky et al. (2007) report that nicotinamide riboside, a new NAD+ precursor, regu-
lates Sir2 deacetylase activity and life span in yeast. The ability of nicotinamide riboside to 
enhance life span does not depend on calorie restriction.The water-soluble vitamin niacin (B3) 
is a building block for NAD+ (nicotina-
mide adenine dinucleotide), which is a 
carrier of two electron equivalents for 
the oxidation of carbohydrates during 
ATP synthesis. Although this redox 
role of NAD+ is well established, there 
is renewed interest in NAD+ metabo-
lism due to recent evidence showing 
that NAD+ regulates diverse path-ways including those controlling life 
span (Ziegler and Niere, 2004). The 
broad-ranging importance of niacin 
metabolites to cellular function is fur-
ther underscored by recent work pro-
viding genetic evidence for the exist-
ence of several additional pathways 
for salvaging the nicotinamide ring 
of NAD+ (Belenky et al., 2007; Bieg-
anowski and Brenner, 2004).Cell 12Belenky et al. (2007) now demon-
strate that a newly described NAD+ 
precursor, nicotinamide riboside 
(NR) (Bieganowski and Brenner, 
2004), contributes to cellular NAD+ 
levels through at least two path-
ways in the budding yeast Saccha-
romyces cerevisiae (Figure 1). Both 
pathways salvage the nicotinamide 
ring for entry into established path-Figure 1. Pathways to NAD+ Synthesis
NAD+ can be generated by the de novo path-
way starting with the precursor tryptophan 
or by the salvage pathway from the precur-
sors nicotinamide (Nam), nicotinic acid (Na), 
and nicotinamide riboside (NR). All of these 
precursors are available from the diet. Niacin 
often refers to two related compounds, nico-
tinamide (niacinamide) and nicotinic acid. 
The yeast gene encoding the enzyme that 
catalyzes each step of NAD+ biosynthesis 
is indicated; recently discovered portions 
of the salvage pathway are shown in blue. 
One arm of the salvage pathway requires 
the phosphorylation of NR to nicotinamide 
mononucleotide (NMN) by the NR kinase 
Nrk1. The other pathway involves the cleav-
age of the NR glycosidic bond by Pnp1 (a 
phosphorylase) and Urh1 (a hydrolase) to 
yield free nicotinamide. Whereas higher eu-
karyotes can readily convert nicotinamide 
to NMN through the action of the salvage 
pathway enzyme nicotinamide phosphoribo-
syl transferase (Revollo et al., 2007), yeast 
primarily hydrolyze nicotinamide to nicotinic 
acid through the nicotinamidase Pnc1 (An-
derson et al., 2003). Curiously, mammals 
do not appear to have a nicotinamidase. 
(Bna6, quinolinate phosphoribosyl trans-
ferase; Qns1, NAD synthetase; Nma, nico-
tinate mononucleotide adenyltransferase; 
Npt, nicotinate phosphoribosyl-transferase; 
PRPP, phosphoribosyl pyrophosphate.)9, May 4, 2007 ©2007 Elsevier Inc. 453
ways of NAD+ synthesis. One path-
way requires the phosphorylation of 
NR to nicotinamide mononucleotide 
(NMN) by the NR kinase Nrk1 (Figure 
1). NMN is then readily converted to 
NAD+ by NMN adenylyltransferase, 
a well-known enzyme of the NAD+ 
salvage pathway. The second path-
way involves the cleavage of the NR 
glycosidic bond to yield free nicotina-
mide (Figure 1). Belenky et al. dem-
onstrate that NR can replace nicotinic 
acid as a vitamin to stably maintain 
intracellular levels of NAD+ levels dur-
ing growth of yeast in liquid cultures 
(Belenky et al., 2007). Utilization of 
NR requires either an active Nrk1 or 
an active Urh1/Pnp1 pathway. In the 
absence of NR supplementation, the 
Nrk1 and Urh1/Pnp1 pathways con-
tribute to NAD+ levels, suggesting that 
endogenous NR may be produced in 
the NAD+ salvage pathway under nor-
mal growth conditions.
The authors link the ability of 
NR to induce NAD+ synthesis with 
increased activity of Sir2 (silent 
information regulator 2) (Belenky et 
al., 2007). Sir2 is an NAD+-depend-
ent histone deacetylase involved in 
gene silencing at telomeres, reduc-
ing the recombination of ribosomal 
DNA (rDNA) and increasing life span 
(reviewed in Haigis and Guarente, 
2006). Yeast strains that exhibit 
lower levels of NAD+ display aber-
rant gene silencing and age rap-
idly. Although caloric restriction is a 
well-established means of increas-
ing life span in diverse organisms, 
the Belenky et al. study indicates 
that NR can extend yeast life span 
through activation of pathways that 
respond to increased NAD+, such as 
those dependent on Sir2.
In mammals, Sir2-related enzymes 
(the sirtuins) are implicated in cell 
survival and the metabolism of fatty 
acids and glucose (Haigis and Guar-
ente, 2006). Several intriguing stud-
ies suggest that enhanced NAD+ syn-454 Cell 129, May 4, 2007 ©2007 Elsevthesis is associated with increased 
sirtuin function (references cited in 
Belenky et al., 2007). However, what 
remains to be determined is how sir-
tuins actually respond to increased 
NAD+ synthesis. It is unclear how an 
increase in intracellular NAD+ from 
1 to 2 mM leads to substantial acti-
vation of Sir2 (Belenky et al., 2007), 
whose Km values are reported in the 
µM range (reviewed in Grubisha et 
al., 2005). Belenky et al. propose that 
the 2-fold increase in NAD+ through 
vitamin supplementation is used 
for discretionary pathways, such as 
those mediated by Sir2. However, it 
is difficult to imagine how the cell dis-
tinguishes essential versus nones-
sential NAD+ utilization, unless there 
were spatially distinct pools of NAD+. 
Another possibility is that NAD+-syn-
thesizing enzymes might physically 
associate and directly channel NAD+ 
into the active site of sirtuins. The 
existence of NAD+ protein sensors 
that respond to appropriate levels 
of NAD+ and modulate sirtuin activ-
ity is another unexplored possibility. 
Moreover, as has been postulated for 
nicotinamide (Anderson et al., 2003), 
increased niacin/NR salvage may 
deplete intermediates that inhibit or 
oppose the function of sirtuins, such 
that it is the derepression of sirtuins 
and not NAD+ synthesis per se that is 
responsible for net activation.
It may not be surprising that cells 
harbor multiple strategies to sal-
vage niacin, an essential molecule 
for all living organisms. Under con-
ditions that result in activation of 
enzymes that increase cleavage 
of NAD+, the cell may protect itself 
from a catastrophic loss of NAD+ 
by increasing expression/activity of 
NAD+ salvage enzymes. Consistent 
with this notion, the yeast nicoti-
namidase Pnc1 is one of the most 
highly expressed genes in response 
to various cellular insults (Anderson 
et al., 2003). Also, expression of NR ier Inc.kinase mRNA is highly upregulated 2 
weeks after sciatic nerve transection 
in rats (Sasaki et al., 2006). There-
fore, it is appealing to suggest that 
NAD+ salvage enzymes are tightly 
linked through bidirectional regula-
tory circuits with NAD+-consuming 
enzymes such as sirtuins and poly 
(ADP-ribose) polymerases. Nutri-
tional status and the availability of 
niacin metabolites may coordinately 
modulate the levels and activity 
of these enzymes. Salvage path-
ways might be especially crucial in 
postmitotic cells (such as neurons) 
where NAD+ salvage might predom-
inate over de novo synthesis, which 
likewise might prevail in actively 
dividing cells. Further studies will 
need to address the importance of 
NR in human health and determine 
whether NR could be an alternative 
niacin supplement/vitamin to treat 
several age-related afflictions such 
as diabetes, atherosclerosis, neuro-
degeneration, and cancer.
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